GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (OTCPK:TYPTF) » Definitions » Common Stock

TYPTF (Tryptamine Therapeutics) Common Stock : $24.58 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Tryptamine Therapeutics Common Stock?

Tryptamine Therapeutics's quarterly common stock increased from Dec. 2022 ($23.15 Mil) to Jun. 2023 ($24.65 Mil) but then declined from Jun. 2023 ($24.65 Mil) to Dec. 2023 ($24.58 Mil).

Tryptamine Therapeutics's annual common stock declined from Jun. 2021 ($26.22 Mil) to Jun. 2022 ($24.11 Mil) but then increased from Jun. 2022 ($24.11 Mil) to Jun. 2023 ($24.65 Mil).


Tryptamine Therapeutics Common Stock Historical Data

The historical data trend for Tryptamine Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Common Stock Chart

Tryptamine Therapeutics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Common Stock
Get a 7-Day Free Trial 5.26 8.80 26.22 24.11 24.65

Tryptamine Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 24.54 24.11 23.15 24.65 24.58

Tryptamine Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Tryptamine Therapeutics Business Description

Traded in Other Exchanges
Address
C/o Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

Tryptamine Therapeutics Headlines